Great achievement by management, probably the best they've...

Great achievement by management, probably the best they've achieved over the last few years.

I guess now it's time to consider the next steps - commercialisation & how does this product position within this new COVID endemic world.

There's currently 10+ RATs approved by TGA with very high sensitivity, meaning >95% PPA.

Let's assume this will be a more attractive option over RATs given the convenience of without having to poke a stick in the nose and wait 15mins, how much would RAP's COVID-19 screening test need to be sold for to remain attractive but also competitive?

RATs are selling at $8-$15 atm and it's readily available at many places. Would RAP be selling this as a per use basis say for $15 each or on a subscription basis?

Just some food for thoughts because some people are already jumping to 'big pharma is looking to takeover' which is unrealistic IMO.

GLTAH and DYOR